Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagloxad Simolenin + TACE in HCC
NCT03608878Phase 2Terminated
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Therapeutic Vaccines, Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adagloxad simolenin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Time to Intrahepatic Total Tumor Volume Progression at 36 months. Started Apr 2019; status: terminated.
02
Drugs
adagloxad simolenin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03608878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608878.